Proteomics

Dataset Information

0

Alagebrium chloride therapy acts to preserve beta cell health


ABSTRACT: Aims/hypothesis AGEs are considered environmental contributors of type 1 diabetes, but the exact role AGEs play early in pathogenesis of the disease, remains unidentified. We aimed to reduce AGEs with the pharmacotherapy alagebrium chloride in MIN6N8 cells and early in life in NOD mice to determine its impact on beta cell immunogenicity, function, and disease progression. Methods MIN6N8 cells were cultured with AGEs with or without short-term alagebrium therapy to determine the effect on ER stress and beta cell antigen presentation via a reporter assay for protein responses in the unfolded protein response, the enzymatic activity of endoplasmic reticulum aminopeptidase-1 (ERAP1) and the immunopeptidome. To determine the effect of short-term alagebrium therapy on beta cells in vivo, female NOD mice were treated with alagebrium and insulin secretion, insulitis, and immune cell repertoire were studied. Adoptive transfer studies and diabetes progression studies were used to consider the impact of alagebrium on immune cell function and disease outcome. Results In MIN6N8 cells, alagebrium therapy inhibited the induction of endoplasmic reticulum (ER) stress and the activity of ERAP1 by AGE-modified proteins. Alagebrium treated-MIN6N8 cells did not change the MHC Class I presentation of known beta cell antigens but did induce proteomic changes related to ER homeostatic pathways. Prior to overt autoimmune diabetes, female NOD mice treated with alagebrium for 30-40 days had improved insulin secretion, reduced insulitis and amplified proportions of pancreatic CD8+ T cells, mature B cells and F4/80+ macrophages. Splenocytes from alagebrium-treated mice adoptively transferred disease to NODscid recipients and maintained interferon production in vitro. While partial protection of islets by alagebrium was seen following the adoptive transfer of activated NOD G9C8 transgenic TCR CD8+ T cells, alagebrium therapy in NOD mice did not reduce diabetes progression. Conclusions/interpretation Our data suggests that in experimental models of diabetes, short-term alagebrium treatment allows for beta cell improvement, and maintenance of immune cell function, which does not fully mitigate diabetes progression.

INSTRUMENT(S): TripleTOF 5600, Orbitrap Fusion

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): B Cell, Cell Culture

DISEASE(S): Type 1 Diabetes Mellitus

SUBMITTER: Pouya Faridi  

LAB HEAD: Anthony Purcell

PROVIDER: PXD025998 | Pride | 2021-06-29

REPOSITORIES: Pride

Similar Datasets

| MSV000086174 | MassIVE
2023-03-11 | PXD035504 | Pride
2024-09-02 | BIOMD0000000381 | BioModels
2016-02-24 | PXD000859 | Pride
2019-03-29 | GSE128315 | GEO
| MSV000086174 | GNPS
2013-11-28 | GSE52815 | GEO
2022-11-10 | PXD025394 | Pride
2024-06-16 | PXD034826 | Pride
2016-03-17 | GSE79200 | GEO